Corporate Deck
Presentations
19
Jan 2024
2024 ASCO GI | CLDN18.2 Chimeric Antigen Receptor T Cell Therapy for Patients with Advanced Gastric and Pancreatic Adenocarcinoma: Results of ELIMYN18.2 Phase 1b Clinical Trial
Jan 19, 2024
12
Dec 2023
2023 ASH | Three-Year Follow-up on Efficacy and Safety Results from Phase I Lummicar Study 1 of Zevorcabtagene Autoleucel in Chinese Patients with Relapsed or Refractory Multiple Myeloma
Dec 12, 2023
13
Nov 2023
2023 SITC | Case Report: Metastatic Gastrointestinal Cancer Patient Responded to Repeated Administration of Anti-Claudin 18.2 CAR-T cells
Nov 13, 2023
07
Jun 2023
2023 ASCO | Circulating Tumor DNA and Association with CAR T-cell Therapy Response in Gastric and Pancreatic Cancer Patients
Jun 07, 2023
06
Jun 2023
2023 ASCO | Phase I Trial of Chimeric Anti-GPC3 scFv-CD3ε Engineered T Cells (CT0180) in Patients with Advanced Hepatocellular Carcinoma
Jun 06, 2023
20
Apr 2023
2023 AACR | CLDN18.2 expression is associated with clinicopathological features and prognosis of Chinese patients with digestive system cancers: a retrospective analysis
Apr 20, 2023